ArticleScience immunology2021
Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study.
Article in Science immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04378777 (A Prospective Cohort Study to Assess Longitudinal Immune Responses in Hospitalized Patients With COVID-19), which is not on this map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Cohort Study to Assess Longitudinal Immune Responses in Hospitalized Patients With COVID-19 (DAIT-COVID-19-002)
Who cites it
54 citing papers in PubMed.
- Virus reactivation in acute and long COVID-19.Nature · 2026Article
- Assessing tensor decomposition quality of immune profiling data from a dictionary learning perspective.bioRxiv : the preprint server for biology · 2026Article
- DNA methylation profiles at hospital admission are associated with subsequent severe COVID-19 outcomes.Clinical epigenetics · 2026Article
- Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19.Nature microbiology · 2026Article
- Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors.Communications medicine · 2026Article
- MTHFR allele and one-carbon metabolic profile predict severity of COVID-19.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Evaluating COVID-19 severity prediction and immune dynamics with NULISAseq: Insights from the IMPACC study.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Acute Respiratory Distress Syndrome Molecular Phenotypes Have Distinct Lower Respiratory Tract Transcriptomes.American journal of respiratory and critical care medicine · 2025Article
- Minimalistic transcriptomic signatures permit accurate early prediction of COVID-19 mortality.JCI insight · 2025Article
- A multiomics recovery factor predicts long COVID in the IMPACC study.The Journal of clinical investigation · 2025Article
- Type 2 immune responses are associated with less severe COVID-19 in a hospitalized cohort.The journal of allergy and clinical immunology. Global · 2025Article
- Circulating endothelial signatures correlate with worse outcomes in COVID-19, respiratory failure and ARDS.Critical care (London, England) · 2025Article
- Longitudinal Meta-cohort study protocol using systems biology to identify vaccine safety biomarkers.Vaccine · 2025Article
- MICBG406A polymorphism reduces risk of mechanical ventilation and death during viral acute lung injury.JCI insight · 2025Article
- Article
- Airway Immune Signatures in Severe and Fatal Infection with COVID-19.American journal of respiratory cell and molecular biology · 2025Article
- Observational research in epidemic settings: a roadmap to reform.BMJ global health · 2025Article
- Association of high γ' fibrinogen levels with adverse events in patients with COVID-19.Blood vessels, thrombosis & hemostasis · 2025Article
- Host-microbe multiomic profiling identifies distinct COVID-19 immune dysregulation in solid organ transplant recipients.Nature communications · 2025Article
- Patients Hospitalized with COVID-19 Demonstrate Distinct Plasma Cytokine and Chemokine Concentrations in vivo and TLR-Mediated Cytokine and Chemokine Production in Whole Blood in vitro.Journal of innate immunity · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The IMmunoPhenotyping Assessment in a COVID-19 Cohort (IMPACC) is a prospective longitudinal study designed to enroll 1000 hospitalized patients with COVID-19 (NCT04378777). IMPACC collects detailed clinical, laboratory and radiographic data along with longitudinal biologic sampling of blood and respiratory secretions for in depth testing. Clinical and lab data are integrated to identify immunologic, virologic, proteomic, metabolomic and genomic features of COVID-19-related susceptibility, severity and disease progression. The goals of IMPACC are to better understand the contributions of pathogen dynamics and host immune responses to the severity and course of COVID-19 and to generate hypotheses for identification of biomarkers and effective therapeutics, including optimal timing of such interventions. In this report we summarize the IMPACC study design and protocols including clinical criteria and recruitment, multi-site standardized sample collection and processing, virologic and immunologic assays, harmonization of assay protocols, high-level analyses and the data sharing plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.